Loading...
  • anti-dengue virus
  • We describe microneutralization assays that used automated 96-well enzyme-linked immunospot (ELI-SPOT) readout instrumentation to measure human anti-dengue virus (DENV) antibodies in CV-1 cells that were stably transfected to express human FcγRIIA (CD32) using conventional Vero cells as a comparator. (ajtmh.org)
  • neutralizing antibody titer
  • In the Phase III study, the seropositive rate was 100% for all Sabin strains after primary immunization, and the neutralizing antibody titer after booster immunization was higher than in the control group (DTaP + OPV). (worldwidescience.org)
  • With this test, the neutralizing antibody titer against HSV-1 could be determined within one day by automated interpretation of the counts of cell spots. (biomedcentral.com)
  • Clinical
  • Clinical diagnosis was performed by a pediatrician who was unaware of the dengue diagnostic test results. (biomedcentral.com)
  • From June 2005 to May 2006, a clinic-based enhanced surveillance system for dengue was implemented in a Puerto Rican municipality to provide a population-based measure of disease incidence and clinical outcomes. (ajtmh.org)
  • We obtained demographic and clinical information from suspected cases and performed serologic and virologic testing. (ajtmh.org)
  • There is no specific treatment available against dengue and clinical management of dengue patients is symptomatic. (frontiersin.org)
  • responses
  • Cell-mediated responses were also evaluated, and higher dengue-specific splenocyte proliferation was observed in cell cultures derived from mice immunized with MWNT-DENV3E when compared to animals immunized with the non-conjugated DENV3E. (biomedcentral.com)
  • Vaccine Development
  • Although genetic similarities among genotypes within a serotype are higher as compared to those among serotypes, differences in the immunogenicity of the included genotypes would be a critical issue in maximizing successful dengue vaccine development. (biomedcentral.com)
  • This review focuses on recent research findings on the dengue host immune response, particularly in humans, and the relevance of these findings to challenges in vaccine development. (biomedcentral.com)
  • disease
  • Doctors need to distinguish between dengue, chikungunya and other diseases to give a successful treatment and prevent the disease spreading. (elsevier.es)
  • Dengue is the most prevalent arthropod-borne viral disease in the world. (biomedcentral.com)
  • Dengue is a vector-borne disease found across much of the world, with an expanding geographical range [ 1 ]. (pubmedcentralcanada.ca)
  • The level of exposure to dengue among the young adults is relatively low despite the endemicity of the disease in Singapore. (ajtmh.org)
  • Dengue is the most important human arboviral disease and a global public health concern throughout tropical/sub-tropical regions. (rborl.org.br)
  • specificity
  • It is known that the cross-reactive response in patients is temporary but few studies have assessed kinetics and potential changes in serum antibody specificity over time. (frontiersin.org)